immunotherapy

Research in Review
Immune Checkpoint Inhibitor New Standard of Care for MSI-H Metastatic Colorectal Cancer
01/25/2017
JCP Editors
The immune checkpoint inhibitor nivolumab has shown durable responses and disease control in pretreated patients with DNA mismatch repair deficient/microsatellite instability high (MSI-H) metastatic colorectal...
The immune checkpoint inhibitor nivolumab has shown durable responses and disease control in pretreated patients with DNA mismatch repair deficient/microsatellite instability high (MSI-H) metastatic colorectal...
The...
01/25/2017
Journal of Clinical Pathways
Research in Review
New Treatment Effective for B-Cell Precursor ALL in Pediatric Patients
11/17/2016
JCP Editors
Single-agent blinatumomab demonstrated antileukemia activity in pediatric patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL), according to a study published in the Journal of...
Single-agent blinatumomab demonstrated antileukemia activity in pediatric patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL), according to a study published in the Journal of...
...
11/17/2016
Journal of Clinical Pathways
Research in Review
Immunotherapies May Pose Severe Heart Risk
11/04/2016
JCP Editors
Researchers have identified a serious and potentially fatal adverse event associated with immunology drugs, according to a study published in the New England Journal of Medicine. Immune checkpoint inhibitors have...
Researchers have identified a serious and potentially fatal adverse event associated with immunology drugs, according to a study published in the New England Journal of Medicine. Immune checkpoint inhibitors have...
...
11/04/2016
Journal of Clinical Pathways
Research in Review
Immunotherapy Drug Improves Overall Survival in Patients With NSCLC
12/30/2015
JCP Editors
Favorable results for pembrolizumab, a PD-1/PD-L1 inhibitor only recently approved for the treatment of non-small-cell lung cancer (NSCLC), were found in a trial comparing the drug’s effectiveness to that of the...
Favorable results for pembrolizumab, a PD-1/PD-L1 inhibitor only recently approved for the treatment of non-small-cell lung cancer (NSCLC), were found in a trial comparing the drug’s effectiveness to that of the...
...
12/30/2015
Journal of Clinical Pathways
Overall Survival for Progressive Bladder Cancer Improved with Personalized Peptide Vaccination
12/01/2015
JCP Editors
A new immunotherapy may help to improve outcomes of patients with metastatic bladder cancer, according to the results of a Phase II study. Bladder cancer is one of the most common and deadly forms of cancer for men...
A new immunotherapy may help to improve outcomes of patients with metastatic bladder cancer, according to the results of a Phase II study. Bladder cancer is one of the most common and deadly forms of cancer for men...
A new...
12/01/2015
Journal of Clinical Pathways
Research in Review
Improved Outcomes for NSCLC Patients with Immunotherapy versus Chemotherapy
10/15/2015
JCP Editors
Researchers from the University of Texas-Southwest Medical Center compared the immunotherapy drug nivolumab with a commonly used chemotherapy drug and found that it improved overall survival with...
Researchers from the University of Texas-Southwest Medical Center compared the immunotherapy drug nivolumab with a commonly used chemotherapy drug and found that it improved overall survival with...
...
10/15/2015
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
LLM Winter Symposium
February 7 ⁠–⁠ February 9
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
GD Solid Tumors
March 22 ⁠–⁠ March 23
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 4
WoundCon
May 1 ⁠–⁠ May 3
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use